Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data

Bookmark and Share
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 8 Dec 2020
Views: 1526
Rating:
Save
Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia

Prof Hertzberg speaks to ecancer about the B-HOLISTIC study which was presented at ASH 2020 and the importance of relapsed/refractory Hodgkin lymphoma real world evidence data. Initially he explains what the B-HOLISTIC study was about and then goes on to mention the key results obtained from this study.

Prof Hertzberg says that results from B-HOLISTIC show that PFS rates remain low in patients with R/R cHL receiving salvage therapy; the greatest risk was among patients with inadequate response to salvage chemotherapy.

The low PFS rates highlight the importance of considering novel targeted therapies to address unmet medical needs. He also highlights that overall, these results from 2010-2013 show that despite the differences in healthcare systems, ethnicities and treatment patterns in B-HOLISTIC, clinical outcomes remain consistent.

Prof Hertzberg then talks about the importance of real world evidence (RWE) data with regards to daily treatment of patients with R/R HL. In the end he mentions a few other studies of importance to R/R HL from ASH that contain RWE data.

This programme has been supported by an unrestricted educational grant from Takeda.